Clinical trial · no report yet · Phase 2
TITAN-RCC
Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma
- NCT02917772 ↗
- Completed
- AIO-Studien-gGmbH
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 17 | |
| Podcasts | 3 | |
| YouTube | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Single Arm Clinical Trial of a Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Carcinoma, Renal Cell; Clear-cell Metastatic Renal Cell Carcinoma
- Interventions
- Nivolumab/Ipilimumab
- Arms
- Nivolumab/Ipilimumab · Experimental
- Enrollment
- 200
- Primary outcomes
- Objective Response Rate (ORR)
- Sponsor
- AIO-Studien-gGmbH with Bristol-Myers Squibb
- Start
- Oct 2016
- Primary completion
- Oct 2021
- Results posted
- No
- Registry record
- NCT02917772 · updated Oct 6, 2022
Publications
linked from the registry- Grimm MO, Esteban E, Barthelemy P, Schmidinger M, Busch J, Valderrama BP, Charnley N, Schmitz M, Schumacher U, Leucht K, Foller S, Baretton G, Duran I, de Velasco G, Priou F, Maroto P, Albiges L; TITAN-RCC study group. Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2023 Nov;24(11):1252-1265. doi: 10.1016/S1470-2045(23)00449-7. Epub 2023 Oct 13. PubMed 37844597